US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Santen Pharm CO ADR
(OP:
SNPHY
)
10.55
-0.57 (-5.13%)
Delayed Quote
Updated: 2:43 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Santen Pharm CO ADR
Santen Joins Inaugural Global Summit for Eye Health as High-Impact Partner
August 05, 2026
From
Santen Pharmaceutical Co., Ltd.
Via
JCN Newswire
SNPHY Stock Earnings: Santen Pharmaceutical Reported Results for Q4 2023
↗
May 17, 2024
Santen Pharmaceutical just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Current Analysis: Santen Pharmaceutical
↗
February 15, 2024
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. Over the past year, Santen's share price rose about 32% from $7.60 to $10.01 as of Thursday’s market...
Via
Talk Markets
